We are live on ! Find out more
RPRX icon

Repros Therapeutics
RPRX

Delisted

RPRX was delisted on the 31st of January, 2018.

80 hedge funds and large institutions have $163M invested in Repros Therapeutics in 2014 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 22 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

46% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 13

32% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 22

7% more funds holding

Funds holding: 75 → 80 (+5)

2% more call options, than puts

Call options by funds: $9.1M | Put options by funds: $8.93M

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

16.67% less ownership

Funds ownership: 84.01% → 67.34% (-17%)

61% less capital inflows, than outflows

Capital inflows: $24.5M | Capital outflows: $62.6M

Holders
80
Holders Change
+5
Holders Change %
+6.67%
% of All Funds
2.12%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
19
Increased
29
Reduced
22
Closed
13
Calls
$9.1​M
Puts
$8.93​M
Net Calls
+$170​K
Net Calls Change
-⁠$2.27​M

RPRX Hedge Fund Activity: Q4 2014 in Review

80 of the 3,765 institutional investors tracked by Wall St. Rank reported a position in Repros Therapeutics (RPRX) for Q4 2014, worth a combined $163M — down 19% from $202M a quarter earlier.

Buyers outnumbered sellers: 19 funds opened new RPRX positions and 13 closed out — a net gain of 6 holders — while 29 added to existing stakes and 22 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $4.86M. The largest seller was Oracle Investment Management, exiting entirely with an estimated $10M sold.

  • 80 institutional investors held Repros Therapeutics (RPRX) as of Q4 2014, up from 75 in Q3 2014.
  • Funds reported $163M of Repros Therapeutics stock for Q4 2014, down 19% quarter-over-quarter.
  • 19 funds opened new Repros Therapeutics positions in Q4 2014 and 13 closed out, a net change of +6 holders.
  • The largest Repros Therapeutics buyer in Q4 2014 was Fidelity Investments, an estimated $4.86M added.
  • The largest Repros Therapeutics seller in Q4 2014 was Oracle Investment Management, an estimated $10M sold.

Based on aggregated 13F filings for Q4 2014.